Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib) research hub

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

This study compares a new version of the drug Trametinib with the existing one, Mekinist. It checks if they're absorbed in the body in the same way. This helps ensure new medications are just as safe and effective for treating certain cancers.